| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.98.25.2829 |
| P698 | PubMed publication ID | 9860783 |
| P50 | author | Harvey D. White | Q1587897 |
| Eric J. Topol | Q5387640 | ||
| Robert Califf | Q19281782 | ||
| A Michael Lincoff | Q63038136 | ||
| P2093 | author name string | Hasselblad V | |
| Moliterno DJ | |||
| Tcheng JE | |||
| Miller DP | |||
| Kong DF | |||
| Harrington RA | |||
| P433 | issue | 25 | |
| P921 | main subject | heart disease | Q190805 |
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 2829-2835 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease | |
| P478 | volume | 98 |
| Q78251271 | 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial |
| Q33380104 | A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention |
| Q59356505 | ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M |
| Q34531478 | Acute ischemic syndromes. Adjunctive therapy |
| Q73138978 | Acute myocardial infarction |
| Q34441606 | Anticoagulation and the heart |
| Q34019038 | Antiplatelet agents in cardiology: the choice of therapy |
| Q33843641 | Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease |
| Q36835862 | Antiplatelet drugs in cardiological practice: established strategies and new developments |
| Q33331052 | Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors |
| Q33822508 | Antiplatelet use in interventional cardiology |
| Q36943257 | Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina |
| Q28169027 | Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI |
| Q28185093 | Aspirin in patients with coronary artery disease: is it simply irresistible? |
| Q33869577 | Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study |
| Q33869581 | Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI. |
| Q43599299 | Cardiac enzyme elevations after percutaneous coronary intervention: myonecrosis, the coronary microcirculation and mortality |
| Q30305766 | Cardiac screening before non-cardiac operations |
| Q78638408 | Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: are we all becoming "interventional" cardiologists? |
| Q28194398 | Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation |
| Q24555072 | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients |
| Q91831348 | Comparing efficacy of receiving different dosages of eptifibatide in bleeding after percutaneous coronary intervention in patients with myocardial infarction |
| Q73289493 | Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease |
| Q35857484 | Considerations in combination therapy: fibrinolytics plus glycoprotein IIb/IIIa receptor inhibitors in acute myocardial infarction. |
| Q73245554 | Coronary Angioplasty |
| Q33947691 | Coronary disease. Acute coronary syndromes: presentation--clinical spectrum and management |
| Q33545464 | Coronary heart disease. Stable and unstable syndromes |
| Q28165924 | Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes |
| Q28168871 | Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes |
| Q35107087 | Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment |
| Q24792342 | Debate: When should we intervene in unstable angina - Time for an old look? |
| Q40709216 | Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists |
| Q30671597 | Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data |
| Q90831449 | Discovery of Aporphine Analogues as Potential Antiplatelet and Antioxidant Agents: Design, Synthesis, Structure-Activity Relationships, Biological Evaluations, and in silico Molecular Docking Studies |
| Q74187733 | Drip and ship: a new strategy for the treatment of acute coronary syndromes |
| Q77060468 | Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience) |
| Q44420954 | Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. |
| Q77375199 | Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics |
| Q57801368 | Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial |
| Q44092049 | Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation |
| Q28165115 | Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study |
| Q28196678 | Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy) |
| Q36927583 | Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability. |
| Q42631922 | Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndrome |
| Q73193128 | Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes |
| Q78163486 | Glycoprotein IIb/IIIa Inhibitors |
| Q74588272 | Glycoprotein IIb/IIIa platelet receptor blockers: are they ready for prime time in patients with unstable coronary artery disease? |
| Q33330501 | Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports |
| Q34130613 | Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluati |
| Q33735570 | Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. |
| Q44304796 | Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions |
| Q52143012 | Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. |
| Q56944701 | Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention |
| Q34820259 | Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors? |
| Q40797559 | Management strategies in unstable coronary artery disease--current problems and future directions. The UCAD Council |
| Q33376977 | Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention |
| Q32076730 | Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention |
| Q56944438 | Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions |
| Q73128810 | Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction |
| Q34147628 | Monitoring antiplatelet therapy: What is the best method? |
| Q35847526 | Multi-bed vascular disease: past, present, and future |
| Q37530424 | New antithrombotic drugs |
| Q42595003 | Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention |
| Q33699818 | Optimal treatment of patients with acute coronary syndromes and non-ST-elevation myocardial infarction |
| Q34027516 | Oral platelet glycoprotein IIb/IIIa inhibition |
| Q33768927 | Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction |
| Q34001532 | Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease |
| Q43966065 | Periprocedural myocardial infarction and mortality: causality versus association |
| Q28189075 | Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects |
| Q28199325 | Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans |
| Q54723126 | Pharmacokinetic and pharmacodynamic properties of batifiban coadministered with antithrombin agents in Chinese healthy volunteers. |
| Q43950261 | Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist |
| Q33334039 | Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes |
| Q56944618 | Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials |
| Q33826201 | Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions |
| Q47229682 | Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events |
| Q34027287 | Recent trials of antithrombotics in the management of patients with acute coronary syndromes |
| Q30307452 | Reperfusion therapy for acute myocardial infarction |
| Q44468433 | Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions |
| Q51815551 | Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects. |
| Q43751969 | Short- and long-term prognostic value of cardiac troponin I and dobutamine echocardiography in patients with stabilized acute coronary syndromes |
| Q28195426 | Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial |
| Q34107084 | Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions |
| Q56944889 | The benefit of abciximab in percutaneous coronary revascularization is not device-specific |
| Q28193081 | The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events |
| Q46156825 | The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis |
| Q33347022 | The role of low-molecular-weight heparin in the management of acute coronary syndromes |
| Q34071460 | The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy |
| Q33333976 | The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease |
| Q35035390 | The vulnerable plaque and acute coronary syndromes |
| Q34086094 | Thrombolytics: drug interactions of clinical significance |
| Q33977931 | Treatment of cardiac diseases: evidence based or experience based medicine? |
| Q33765444 | Triggers, targets and treatments for thrombosis |
| Q52537663 | Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution. |
| Q40737172 | Unstable Angina |
| Q41907771 | Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade |
| Q33588350 | Update in internal medicine |
| Q81359097 | [Acute coronary syndrome: unstable angina and myocardial infarction] |
Search more.